Tessa Arends, PhD, and Katy de Valle, PhD, were awarded this year’s Young Investigator Prize, announced at the 32nd Annual International Research Congress (IRC) on FSHD in Amsterdam earlier this […]
In case you missed it, the long-awaited and first-of-its-kind digital research and health platform, BetterLife FSHD, launched last fall. In our video below (scroll to the bottom of the page), […]
Author: Ashley Ferreira, FSHD Society The REACH Phase 3 clinical trial, conducted by Fulcrum Therapeutics, aimed to evaluate the efficacy of losmapimod in treating facioscapulohumeral muscular dystrophy (FSHD). Despite promising […]
In early June 2025, Avidity shared promising results from their Phase 2 clinical trial. Participants who received the treatment showed noticeable improvements in strength and function compared to those on […]
An announcement from Avidity Biosciences to the FSHD community: June 9, 2025 Dear FSHD Community, Today, we are very pleased to share multiple milestones related to the delpacibart braxlosiran (del-brax) […]
English English 
العربية
Español de México
Français du Canada
简体中文
